Surrozen, Inc. SRZN

Healthcare — Biotechnology

Insider Buys (last 12m)

Insider Buys alert about insiders buying in the last 12 month

Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)

Financial statements are limited to most recent four years or quarters for non-powerpack users

Ten years worth of data (where available), most important trends and XLS exports are available for our Powerpack users.

	Sep '20	Dec '20	Mar '21	Jun '21	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
P/E ratio	—	—	—	—	—	—	—	—	—	‡‡‡	—	—	—	—	—	—	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
P/S ratio	—	—	—	—	—	—	—	—	—	‡‡‡	—	—	—	—	—	—	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
P/FCF ratio	—	—	—	—	—	—	—	—	—	‡‡‡	—	—	—	—	—	—	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
P/Operating CF	—	—	—	—	—	—	—	—	—	‡‡‡‡‡	—	—	—	—	—	—	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
P/B ratio	—	—	—	—	—	—	—	—	—	‡‡‡‡‡	—	—	—	—	—	—	‡‡‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Price to Tangible BV	—	—	—	—	—	—	—	—	—	‡‡‡‡‡	—	—	—	—	—	—	‡‡‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
EV/Sales	—	—	—	—	—	—	—	—	—	‡‡‡	—	—	—	—	—	—	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EV/EBITDA	—	—	—	—	—	—	—	—	—	‡‡‡‡‡	—	—	—	—	—	—	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
EV/Operating CF	—	—	—	—	—	—	—	—	—	‡‡‡‡‡	—	—	—	—	—	—	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EV/FCF	—	—	—	—	—	—	—	—	—	‡‡‡‡‡	—	—	—	—	—	—	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Quick Ratio	0.00	0.28	0.79	0.25	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Current Ratio	0.00	0.51	1.43	0.59	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Net Debt/EBITDA	0.00	2.25	0.06	0.03	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Debt/Assets	0.00%	0.00%	0.00%	0.00%	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Debt/Equity	0.00	0.00	0.00	0.00	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Asset Turnover	0.00	0.00	—	—	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Operating CF/Net income	2.29	(43.15)	0.79	1.02	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Capex/Depreciation	(0.28)	(0.28)	(0.67)	(0.12)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Interest Coverage	0.00	—	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Research and Development Expense of Revenue	0.00%	—	0.00%	0.00%	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Selling, General and Administrative Expense of Revenue	0.00%	0.00%	0.00%	0.00%	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Intangible Assets out of Total Assets	0.00	0.00	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Share Based Compensation of Revenue	0.00%	—	0.00%	0.00%	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Graham Net Nets	—	—	—	—	—	—	—	—	—	‡‡‡‡‡	—	—	—	—	—	—	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Graham Number	—	—	—	—	—	—	—	—	—	‡‡‡	—	—	—	—	—	—	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Earnings Yield	—	—	—	—	—	—	—	—	—	‡‡‡‡‡	—	—	—	—	—	—	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Free Cash Flow Yield	—	—	—	—	—	—	—	—	—	‡‡‡‡‡	—	—	—	—	—	—	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Revenue per Share	0.00	0.00	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Operating CF per Share	(16.01)	1.58	(8.53)	(10.60)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Capex per Share	(0.34)	0.03	(0.28)	(0.05)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Free Cash Flow per Share	(16.34)	1.61	(8.82)	(10.65)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Cash per Share	0.00	0.08	0.64	0.32	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Shareholders Equity per Share	0.00	7.56	4.13	4.11	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Interest Debt per Share	0.00	0.00	0.00	0.00	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Book value per Share	0.00	7.56	4.13	4.11	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Free Cash Flow	(20.18)	19.24	(10.67)	(12.94)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Working Capital	(0.03)	(1.73)	0.42	(0.63)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Capital Expenditures	(0.41)	0.41	(0.34)	(0.06)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Net Current Asset Value	0.00	(1.73)	(87.03)	(87.03)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Receivables	—	—	—	—	—	—	—	—	—	—	—	—	—	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Payables	—	—	—	—	—	—	—	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Assets	75.34	115.47	—	—	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Common Equity	61.88	99.98	—	—	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EV/EBIT	—	—	—	—	—	—	—	—	—	‡‡‡‡‡	—	—	—	—	—	—	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Capex to Sales	0.00	0.00	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Price to Operating Income	—	—	—	—	—	—	—	—	—	‡‡‡	—	—	—	—	—	—	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡

Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Subscribe now